Quarterly ResultJul 28, 2026, 04:18 PM
Chemed Q2 Revenue +8.8% to $673.3M; Adj. EPS $6.06; Raises FY26 Guidance
AI Summary
Chemed Corporation reported strong financial results for Q2 2026, with consolidated revenue increasing 8.8% to $673.3 million and adjusted diluted EPS rising 41.9% to $6.06. The VITAS segment showed significant growth, driven by increased patient revenue and admissions, while the Roto-Rooter segment experienced modest revenue growth. The company also raised its full-year 2026 adjusted diluted EPS guidance to $25.00-$25.75 and repurchased $89.8 million in shares during the quarter.
Key Highlights
- Consolidated revenue increased 8.8% to $673.3 million in Q2 2026.
- Adjusted diluted EPS rose 41.9% to $6.06 for the quarter.
- VITAS net patient revenue grew 11.9% to $443.3 million.
- Roto-Rooter revenue increased 3.3% to $229.9 million.
- Company repurchased 210,000 shares for $89.8 million in Q2 2026.
- Full-year 2026 adjusted diluted EPS guidance raised to $25.00-$25.75.
- VITAS full-year ADC growth guidance increased to 5.75%-6.25%.
- VITAS Medicare Cap billing limitation reduced to $7,000 for full year.
Price Impact
More from CHE